Last mentioned: Mar 19, 2026
Healthy China 2030
Target deadline for major health indicators to reach developed nation levels.
Mid-term Review
Assessment of biotech self-sufficiency and AI integration metrics.
Filing Guidance Issued
Official guidance released for companies missing deadlines due to the outage.
Guidance Issued
The registrar advises companies to document filing errors and promises to take the outage into account for deadlines.
Vulnerability Reported
Dan Neidle of Tax Policy Associates alerts Companies House to the 'back key' security flaw.
Service Suspension
Companies House takes the WebFiling service offline on Friday evening to investigate the issue.
Guidance Issued
Official guidance released advising users on how to handle missed filing deadlines due to the outage.
Vulnerability Discovered
Dan Neidle identifies a critical session management flaw in the WebFiling dashboard.
Companies House Alerted
Tax Policy Associates notifies the UK corporate register of the security risk.
Service Suspension
Companies House takes the WebFiling service offline for investigation and patching.
Vulnerability Identified
Dan Neidle of Tax Policy Associates discovers that the 'back' button allows access to other companies' private data.
Agency Alerted
Companies House is formally notified of the security flaw by Tax Policy Associates.
Service Suspension
Companies House takes the WebFiling portal offline on Friday evening to investigate the breach.
Trial Failure Announced
Roche confirms the oral SERD candidate failed to meet primary endpoints; shares dip immediately.
Official Launch
The 15th Five-Year Plan is formally adopted at the National People's Congress.
Phase II Data Review
Earlier data had suggested potential efficacy, leading to high investor expectations for the Phase III results.
Drafting Phase
Central Committee begins finalizing the 15th FYP healthcare targets.
Combination Trials Launch
Roche expanded the program to include combination therapies with CDK4/6 inhibitors.
China’s 15th Five-Year Plan (2026-2030) prioritizes 'biotech sovereignty' and the aggressive integration of AI to manage an aging population. The plan signals a strategic shift toward total domestic self-reliance in high-end medical devices and innovative drug development.
DocGo is successfully transitioning from large-scale government contracts to high-growth remote patient monitoring and mobile health services, while specialty firms like Kyntra Bio and Assertio are streamlining operations to focus on core clinical assets. These shifts reflect a broader industry trend toward sustainable, technology-driven care models and disciplined capital allocation.
The UK’s corporate registrar, Companies House, has taken its WebFiling service offline following the discovery of a critical security flaw that exposed sensitive director data. The vulnerability allowed unauthorized users to view and potentially edit corporate records, raising significant concerns regarding identity theft and corporate fraud.
Companies House has taken its WebFiling service offline following the discovery of a severe vulnerability that allowed users to view and edit the personal data of other businesses. The flaw, which exposed directors' home addresses and dates of birth, was triggered by a simple browser navigation action, raising significant concerns over corporate identity theft and fraud.
The UK’s Companies House has taken its WebFiling service offline following the discovery of a critical security flaw that allowed users to view and edit sensitive personal data of company directors. The vulnerability, which could be exploited simply by using a browser's back button, has raised significant concerns regarding corporate identity theft and the integrity of the UK's business register.
Mineralys Therapeutics (MLYS) reported a narrower-than-expected Q4 2025 loss and confirmed the FDA's acceptance of its New Drug Application for lorundrostat. The company is now pivoting toward commercial readiness for its lead hypertension candidate while maintaining a robust clinical pipeline in chronic kidney disease.
Mineralys (MLYS) and Vuzix (VUZI) reported Q4 2025 results, highlighting divergent but critical paths in healthcare innovation: the clinical validation of next-generation hypertension therapies and the operational scaling of augmented reality in surgical settings. While Mineralys focuses on pivotal trial readouts for lorundrostat, Vuzix is navigating a transition toward OEM and high-margin medical software solutions.
Ipsen has appointed Michelle C. Werner as Executive Vice President and President of North America, effective March 2026. A veteran of AstraZeneca and former CEO of Alltrna, Werner is tasked with accelerating growth in Ipsen's largest market across its oncology, rare disease, and neuroscience portfolios.
Ipsen has appointed industry veteran Michelle C. Werner as Executive Vice President and President of North America, effective immediately. Werner, who joins from Flagship Pioneering and Alltrna, will oversee the company's largest geographic market as it accelerates its specialty care strategy in oncology and rare diseases.
Roche shares declined following the announcement that its oral SERD, giredestrant, failed to meet the primary endpoint in a pivotal Phase III trial for advanced breast cancer. The setback marks a significant blow to Roche's efforts to regain dominance in the HR-positive, HER2-negative oncology market.
Roche's stock fell on March 9, 2026, following the failure of its oral breast cancer candidate in a key clinical trial. This setback complicates the Swiss pharmaceutical giant's efforts to modernize its oncology portfolio and compete in the lucrative oral SERD market.
Lexicon Pharmaceuticals is set to report Q4 2025 results, with investors laser-focused on the commercial trajectory of heart failure drug Inpefa and the regulatory path for sotagliflozin in Type 1 Diabetes. The briefing examines the company's financial health and the strategic importance of its neuropathic pain candidate, LX9211.
The FTSE 100 opened significantly higher on Thursday as market analysts officially coined the 'HALO' trade, a new thematic grouping of UK blue-chips. This shift signals a strategic pivot by institutional investors toward London's value-driven giants amid a cooling global interest rate environment.
AstraZeneca CEO Pascal Soriot's total compensation for 2025 reached £17.7 million, driven by significant performance-linked bonuses. The payout reinforces Soriot's position as one of the highest-paid executives in the FTSE 100 as the company pursues an ambitious $80 billion revenue target by 2030.
AstraZeneca CEO Pascal Soriot’s total remuneration for 2025 reached £17.7 million, driven by strong corporate performance and long-term incentives. The payout highlights the ongoing tension between UK executive pay standards and the global competition for pharmaceutical leadership talent.
A widespread media narrative is challenging the clinical hegemony of statins, highlighting a perceived lack of transparency regarding side effects and alternative cardiovascular therapies. This shift in public discourse signals a growing demand for patient autonomy that could impact the long-term market share of traditional lipid-lowering blockbusters.